Native Meta creative and exact outbound link observed October 22, 2026. Redirects were followed to the captured public destination. Advertiser claims are source material; activity does not establish performance. No personal, health or payment details were entered.

A treatment offer develops through customer stories, product education, the care process and a clear purchase entry. Compare the creative with the destination and explore the other ads sharing this route.
Selected for its design and offer structure. Ad performance isn’t available in this collection.
Letting customers make the case is the right call for a brand asking people to trust it with a prescription. The center review is believable because it isn't perfect: the reviewer says the pharmacy took a while at first but has been fast more recently, and that deliveries arrive within two days. The reviews in the collage are about service (a smooth process, a provider who gets back quickly, customer service) rather than results, which keeps the proof on what Brello controls.
Only the center review is readable on a phone; the rest are cropped and tiny, so the collage looks like proof without being read as proof. There's no star average or review count on the frame either, even though Brello's other statics show a Trustpilot badge with 4K reviews. Pull one short line from the center review into large type above the banner, and add the rating badge so the collage has a headline number.
The pile of reviews signals lots of customers before any single one is read.
A detailed, slightly mixed review is more credible than a short rave.
The offer sits on top of the proof, so the price is read in the context of happy customers.
It supplies the inclusions the collage doesn't show.
GLP-1 Tirzepatide at $166/month (if approved), with fine print noting a three-month minimum that renews for $499 every 11 weeks until cancelled.
The ad sends people to tirzepatidewoo.brellohealth.com, a dedicated Tirzepatide offer page rather than the homepage or a quiz, and it's one of 18 Brello ads in the library that point there. This is one of the better matches in the set, because the page's customer stories section comes right after the hero and continues the ad's idea: Trusted by 80,000+ members, a Trustpilot rating based on 4,000+ reviews, and review cards about customer service and community. Some of the page's reviews go further than the ad's, describing pounds lost, so they read as individual stories the brand chose to feature. Keeping the service-focused reviews first, as the ad does, would make the handoff even smoother.
Brello's dedicated Tirzepatide offer page opens on a $166 a month special with the three-month plan box, then moves through reviews, treatment education, a four-step care path, inclusions and FAQs. It's where 18 Brello ads in the library land, all static image ads, built on emotional moments, native-style text posts and offer or inclusion lists.
A price lock banner, the vial with a $166 badge, and a plan box with the $499 three-month plan, Trustpilot rating, transfer note and intake explanation, answering what it costs and what happens when you pay.
Trusted by 80,000+ members with a Trustpilot rating and review cards about community, customer service and members' own results, answering whether people like you have done this.
A deeper look inside Tirzepatide, with a short explanation, a list of what studies examine, footnoted sources and a results-may-vary note, answering what the medication is.
A straightforward path to care in four photo steps (select your plan, provider review, ships to your door, ongoing support), answering how the process works.
What makes Brello different, with six inclusions beside a photo and a Take the First Step button, answering what you get beyond the medication.
Six questions on approval, refunds, timelines and replacements, then the study references, disclaimers and plan terms, answering the last practical doubts.
Read the full breakdown of this page
One of 22 Brello Health ads in the Fluid Inspiration Library, captured from the Meta Ad Library on Oct 22, 2026. We record that an ad ran publicly, not how it performed.